Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma

Chemotherapy

Volumn 58, Issue 6, 2013, Pages 468-474

  Park, Seong Joon ^a   Lee, Jae Lyun ^a   Park, Inkeun ^a   Park, Kwonoh ^a   Ahn, Yongcheol ^a   Ahn, Jin Hee ^a   Lee, Dae Ho ^a   Ahn, Shin ^a   Song, Cheryn ^a   Hong, Jun Hyuk ^a   Kim, Choung Soo ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

First line therapy; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875645855     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000346484     Document Type: Article

References (27)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125-134.
2. Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, Cho JH, Lim HY: Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. Chemotherapy 2010; 56: 485-491.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del- Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 3584-3590.
4. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574.
5. Wilhelm SM, Carter C, Tang L, Wilkie DMcNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 64: 7099-7109.
6. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM: Randomized phaseII trial of first-line treatment with sorafenib versus interferon alfa- 2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-1289.
7. National Comprehensive Cancer Network (NCCN): National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Kidney Cancer. Fort Washington, NCCN, 2011.
8. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor- targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
9. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B: Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011; 22: 1812-1823.
10. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee S-H, Haanen J, Castellano D, Vrdoljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded- access trial. Lancet Oncol 2009; 10: 757-763.
11. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor- targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
12. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-524.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, SargentD, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
14. Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, Shen Y, Zhu Y, Ye D, Huang Y: Efficacy of sorafenib on metastatic renal cell carcinomain Asian patients: results from a multicenter study. BMC Cancer 2009; 9: 249.
15. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-762.
16. Rini B, Szczylik C, Tannir N, Koralewski P, Tomczak P, Deptala AKracht K, Sun Y, Puhlmann M, Escudier B: AMG386 in combination with sorafenib in patients with metastatic renal cell carcinoma: randomized, doubleblind, placebo-controlled, phase II study. J Clin Oncol 2011, abstr 309.
17. Stadler WM, Figlin RA, McDermott DF,Dutcher JP,Knox JJ,Miller WH Jr,Hainsworth JD,Henderson CA,George JR,Hajdenberg J,Kindwall-Keller TL,Ernstoff MS,Drabkin HA,Curti BD,Chu L,Ryan CW,Hotte SJ,Xia C,Cupit L,Bukowski RM. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 2010; 116:1272-1280.
18. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B: Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy inpatients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006; 42: 548-556.
19. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB: Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594-1598.
20. Amato RJ: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (mRCC). ASCO Annual Meeting 2008, abstr 5122.
21. Motzer RJ: Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal effect trial. Genitourinary Cancer Symposium 2011, abstr LBA308.
22. Porta C, Procopio G, Carteni G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E: Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011; 108:E250-E257.
23. Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary MDuh MS: Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 2011; 11: 105.
24. Ratain MJ, Eisen T Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
25. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12:426-437.
26. Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ, Zhong LH, Wahid MI: Kidney cancer working group report. Jpn J Clin Oncol 2010; 40(suppl 1):i51-i56.
27. Eisen T,Oudard S,Szczylik C,Gravis G,Heinzer H,Middleton R,Cihon F,Anderson S,Shah S,Bukowski R,Escudier B. Sorafenib for older patients with renal cell carcinoma: subset analysis from arandomized trial.J Natl Cancer Inst 2008; 100: 1454-1463.